RP Management, an investor in royalty streams from pharmaceuticals, offered to buy Elan Corp. for about $6.5 billion, threatening the Irish drugmaker's plan to embark on its own acquisitions.
Royalty Pharma offers $6.5B to acquire Elan
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.